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Abstract 
High grade gliomas (HGGs) are aggressive primary brain tumours with local invasive growth and 
poor clinical prognosis. Clinical outcome is compounded by resistance to standard and novel 
therapeutics. We have evaluated reformulated aspirin (IP1867B) alone and in combination with 
conventional and novel anti-aHGG agents. We show that recent biopsy-derived aHGG models were 
highly resistant to conventional therapeutics although show sensitivity to IP1867B, a reformulated 
“liquid” aspirin. IP1867B treatment mediated a potent suppression of the IL6/STAT3 and NF-κB 
pathways and observed a significant reduction in EGFR transcription and protein expression. We 
observed the loss of the insulin-like growth factor 1 and insulin-like growth factor 1 receptor 
expression at both the transcript and protein level post IP1867B treatment. This increased sensitivity 
to EGFR inhibitors. In vivo, IP1867B was very well tolerated, had little-to-no gastric lesions versus 
aspirin and, directed a significant reduction of tumour burden with suppression of EGFR, IGF1 and 
IGFR1. With EGFR inhibitors, we noted a potent synergistic response in aHGG cells. These data 
provide a rationale for further investigation of IP1867B with a number of anti-EGFR agents currently 
being evaluated in the clinic. 
1. Introduction 
In 2017, 80,000 patients in the US and 11,400 in the UK were diagnosed with a primary brain 
tumour [1] [2]. Paediatric high grade glioma frequency in the US are 5.7 cases per 100,000. Adult 
HGG treatment comprises surgical resection and combined radio- and chemo-therapy [3,4]. The 
standard chemotherapeutic is temozolomide (TemodalTM) (TMZ), an oral DNA alkylating agent [5–
7]. TMZ and radiotherapy (the “Stupp protocol”) demonstrated significant patient survival benefit 
versus radiotherapy alone, showing a median increase in survival of 2.5 months [3,4,8]. Cohort 
analysis revealed a discernible clinical response only in adult high grade glioma (aHGG) patients 
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exhibiting promoter methylation of O6-methylguanine DNA methyltransferase (MGMT) [9]. 
Irrespective of MGMT promoter methylation, almost all aHGG patients exhibited eventual disease 
progression. An area that has attracted attention is the repurposing of Food and Drug Administration 
(FDA) approved agents for difficult-to-treat cancers, in particular high grade gliomas [10–12].  
Aspirin (acetylsalicylic acid, ASA) is a nonsteroidal anti-inflammatory drug which inhibits the 
cyclooxygenase (COX) enzymes COX-1 and COX-2 [13] and has been implicated in anti-cancer 
responses [14]. Aspirin use post-diagnosis improved patient outcome, suggesting a role with 
conventional therapies [15]. The long-term use of aspirin reduced the cancer risk in paediatric patients 
with constitutional mismatch repair deficiency who are predisposed to cancer development [16]. 
There are over 20 registered clinical trials of aspirin for cancer therapy [17]. Aspirin solubility is low 
(1 g in: 300 mL water at 25OC) and there are serious concerns regarding gastrointestinal (GI) injury 
in patients prescribed aspirin long-term. Even low dose aspirin can induce duodenal mucosal injury 
including ulcers or haemorrhages.  
Approximately 50% of aHGG display EGFR amplification. Further, a number of aHGGs 
express a truncated EGFR (EGFRvIII) protein which is generated following the removal of exons 2–
7 [18,19] that displays constitutive, ligand-independent tyrosine kinase activity [20]. Insulin Like 
Growth Factor 1 Receptor (IGF1R) is rarely mutated or amplified in aHGG [21], where, activation of 
this network is considered ligand-dependant via endocrine mechanisms. IGF1R targeting has a 
significant impact on AKT signalling in aHGG [22], and is implicated in EGFR inhibitor resistance 
[23]. 
We report that IP1867B (ASA/triacetin/saccharin) directed a potent anti-aHGG response in 
vitro and in vivo. This was via suppression of the IL6/STAT3, NF-κB, IGF1/IGFR1 signalling 
networks. IP1867B exposure induced the down regulation of EGFR, at both protein and transcript 
level. IP1867B was well tolerated in non-neoplastic astrocytes and showed no associated in vivo GI 
toxicity. IP1867B synergised with EGFR inhibitors and in combination with IGF1R inhibitors had 
no additive effect.  
2. Materials and Methods. 
Tumour specimens and primary tumour cultures. Adult HGG biopsy samples were obtained from 
patients undergoing biopsy surgery at Kings College Hospital NHS Foundation Trust (LREC review 
board (11/SC/0048) London, UK). Tumours were classified based on WHO criteria [1] after 
examination by neuro-pathologists. Tumour mass was mechanically dissociated into explant clumps, 
incubated at 37oC to allow neoplastic cells to colonize the flask/cell culture plates. Medium was 
changed every 2 days. When neoplastic cells reached confluence, cells were passaged and expanded. 
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Once passage 1 cells were obtained, Short Tandem Repeat (STR) analysis was conducted to enable 
subsequent cell line authentication (Agilent Bioscience). 
Chemotherapeutics and Cell Culture. IP1867B (Innovate Pharmaceuticals), TMZ (T2577), 
vincristine (V0400000) and aspirin (Sigma-Aldrich). Gemcitabine (S1714), Gefitinib or AZD3759 
(SelleckChem). Adult glioma cell line U87MG was obtained from the ATCC and maintained in 
DMEM supplemented with 10% heat inactivated FCS (Sigma-Aldrich). Novel aHGG biopsy-lines 
UP-029, SEBTA-003, SEBTA-023 and SEBTA-025 were cultured in DMEM medium. CC2565 non-
neoplastic astrocytes (Lonza) were maintained in astrocyte growth medium supplemented with 
SingleQuots™ (CC-3187 Lonza) including (CC-4123): rhEGF, insulin, ascorbic acid, L-glutamine. 
Cells were cultured under normoxic (21%) or hypoxic (1%) O2 conditions. 
MTS cell viability assay. 5 x103 cells were seeded in triplicate in a 96 well plate. 24 hours post 
seeding, cell lines were treated with each agent. CellTiter 96® AQueous One Solution MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)) Reagent 
(G3580 Promega) was added and absorbance at 490nm recorded.  
Western blot analysis. Cells were harvested and lysed using RIPA buffer (89900, Thermo-Fisher) 
and 1x protease inhibitor cocktail (78442 Thermo-Fisher). 50 μg total protein was loaded per sample 
and separated by SDS-PAGE. Proteins were transferred onto PDVF membrane (BioRad). Membranes 
were blocked for 1 hour at room temperature (RT) in Odyssey blocking buffer (972-46100 LICOR). 
Primary antibodies (Supplemental Table 1) were added overnight at 4°C. Secondary antibody were 
added (LICOR) at 1:10000 dilution for 1 hour at RT and membranes imaged on an Odyssey CLX 
(Licor). All uncropped immunoblots are shown in Supplemental Figures 1-5. 
Quantitative real time PCR. Total RNA was extracted (RNAeasy, 74104 Qiagen) and measured 
using RNA6000 chip (Agilent Bioscience, UK). 0.5 μg total RNA was used per cDNA synthesis 
reaction (iScript cDNA synthesis kit, 1708890 BioRad). Real Time PCR was performed using a 
LightCycler 96 (Roche) (iTaq SYBR Green, 1725120 BioRad). Primer sequences shown in 
supplemental Table 1. Data analysis was carried out using the 2-∆∆CT method [24]. 
RT2 pathway transcriptomics and analysis. Total RNA was extracted per condition (NT, 6hr 
IP1867B) using the RNeasy Plus Mini Kit (Qiagen) including genomic DNA removal. The quantified 
by RNA 6000 Nano Kit (Agilent, UK). 0.5 μg of RNA was used for RT2 cDNA (Qiagen, UK). cDNA 
was added on the cell death Pathway Finder (PAHS-212Z), NF-κB signalling array (Qiagen, PAHS-
025Z) and IL6/STAT3 signalling pathway (PAHS-160Z). Plates were run using a Light Cycler 96 
(Roche, UK). The CT values were obtained and fold changes determined by 2-∆∆CT [24]. 
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In vivo anti-tumour efficacy. 250,000 U87-luciferase cells were inoculated (intra-cranially) into 
NOD/SCID mice (aged 10-12 weeks). Animals were grouped based on luciferase imaging. Treatment 
was initiated every three days via IP injection, PBS, TMZ 50 mg/Kg/day or IP1867B 30mg/Kg/day. 
In vivo bioluminescent imaging was performed once per week and all animals were weighed with 
behaviour and neurological signs (including altered gait, tremors, seizures and/or lethargy) monitored 
daily. This animal study was conducted with Institutional and Home Office ethical approval. 
In vivo gastric studies. Female C57BL/6 mice (aged 10-12 weeks, n=2-3 mice/group) were fasted 
for 16 hours and oral gavaged daily for 5 consecutive days with 1% methylcellulose (10 ml/kg), 
IP1867B (30 mg/kg) or aspirin (30 mg/kg). All animal studies were conducted with Home Office 
ethical approval. Stomachs were extracted and opened along their greater curvature and pinned to a 
bed of paraffin and formaldehyde fixed.   Stomachs were cut into strips containing antrum and corpus 
and processed for standard H&E staining.  Non-serial sectioned gastric mucosae were assessed for 
lesion number (521 ± 112 mm/stomach).  All animal studies were conducted with Institutional and 
Home Office ethical approval.  
Data analysis and statistics. Studies were analysed using GraphPad Prism and are represented as 
mean ± St.Dev. Statistical significance calculated using Student’s t-test, (*P ≤ 0.05), two-tailed 
ANOVA analysis, or the log-rank test for Kaplan Meier survival analyses. 
3. Results 
IP1867B demonstrates a potent in vitro anti-aHGG effect under both normoxic and hypoxic 
conditions.  
  We investigated how novel biopsy-derived aHGG responded to each excipient, IP1867B and 
temozolomide (TMZ) (Figure 1). 96 hours post drug treatment MTS viability assays were conducted 
and EC50 values determined (Figure 1A-D). Saccharin did not affect cell viability at even the highest 
tested concentration of 36.5 mM. Triacetin significantly reduced cell viability although this was only 
at dosages >290 mM. When treated with aspirin alone, aHGG cells show limited cell death. The 
maximal solubility of aspirin (SIGMA Aldrich) was 3 mg/mL (16.65 mM). We were unable to 
dissolve aspirin at this concentration as significant particulate was observed. The highest 
concentration used was 1 mg/mL (5.55 mM).  Reduced aHGG cell viability was only observed at 500 
μM aspirin. We noted a significant reduction in aHGG cell viability following IP1867B treatment. 
Aspirin alone (SIGMA) and IP1867B noticeably changed the pH of the medium, consistent with high 
concentration acetylsalicylic acid. This alone did not account for the reduced cell viability as IP1867B 
significantly reduced aHGG cell viability at lower concentrations (Figure 1).  
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We determined the overall EC50 for each component and for TMZ (Figure 1E). Following a 
single treatment, IP1867B was significantly more potent compared to each agent and single dose 
TMZ exposure, a response conserved in a number of aHGG cell lines. The aHGG lines demonstrated 
high tolerance to single dose treatment with TMZ, particularly SEBTA-023, SEBTA-003 and UP-
029 that display unmethylated MGMT promoters. Representative microscopy images of each aHGG 
cell line 24 hour post IP1867B exposure revealed widespread cell death post-IP1867B treatment that 
was not observed post-treatment with any of the excipient components with only limited cell 
detachment/death post-TMZ treatment (Figure 1F). 
Adult HGG therapeutics need to be effective under both normoxic (21% O2) and hypoxic (1% 
O2) conditions. Cells were incubated under hypoxic conditions and treated with IP1867B. At 96 hours 
MTS assays were conducted (under either hypoxic or normoxic conditions) and EC50 concentrations 
determined for each (Figure 1G).  Irrespective of the environment, there was a significant reduction 
in cell viability post-IP1867B treatment. However, there was no significant difference between the 
EC50 values for each aHGG line cell under normoxic or hypoxic conditions post-IP1867B exposure.  
IP1867B formulation demonstrates synergy compared to each individual excipient component 
and increased the effectiveness of TMZ.  
 We questioned if the IP1867B formulation had a synergistic effect on treated aHGG cells. We 
determined the effective concentration for aspirin (SIGMA) (16 μM) and triacetin (0.6 mM) alone, 
an effective concentration for aspirin (SIGMA), triacetin and saccharin (the three excipients 
individually combined at 11 μM, 0.5 mM and 500 mM respectively) and finally for TMZ alone (9.1 
μM). Single/dual agents were added simultaneously and were compared to IP1867B (Figure 2A-D). 
Treatment with aspirin (SIGMA) and TMZ was additive (where the TMZ EC50 fell between 6.1 - 
27.2 μM for each aHGG cell line). While there was a reduction in cell viability, this reduction was 
not statistically significant. When aspirin (SIGMA) and triacetin were used in combination to treat 
aHGG cells no significant change was noted. A potent synergistic response was observed when 
IP1867B was compared to each excipient component, or when the three individual components were 
independently combined (Figure 2E). When aspirin (SIGMA) and TMZ were used in combination, 
there was no significant difference in overall aHGG cell viability indicating that the combination of 
these in vitro did not have an additive effect (TMZ EC50 remained at 12.1 μM) (Figure 2F). IP1867B 
and TMZ when used together, showed an additive effect where the EC50 was ≈0.5 μM (Figure 2G). 
We concluded that IP1867B was highly synergistic compared to each excipient component alone and 
while aspirin (SIGMA) and TMZ in combination did not significantly affect cell viability (either 
synergistic or additive), IP1867B and TMZ did have an additive response. We questioned if non-
neoplastic cells were sensitive to IP1867B. Non-neoplastic CC2565 astrocytes were exposed to each 
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individual component or to IP1867B (Figure 2H). At 96 hours post IP1867B, CC2565 cells did not 
display a significant reduction in overall viability. IP1867B showed cancer-selectivity (EC50 
concentration(s) for aHGG was between 0.39-0.6458 μM and the CC2565 EC50 was 10.16 μM) (P = 
0.0038).   
IP1867B treatment induces the potent suppression of NF-κB and IGF1R 
We examined how IP1867B could mediate this response. We tested if there was significant 
caspase 3 cleavage following treatment with the IP1867B (Figure 3A). There was the significant 
detection of cleaved caspase 3 at 96 hours post-treatment. We questioned if there was p53 
accumulation and activation. We did not see discernible p53 accumulation although noted p53 
phosphorylation (Ser15 and Ser46) (Figure 3B). In SEBTA-023 aHGG cells we were unable to detect 
any p53. To complement this study, each aHGG cell line was exposed to IP1867B or TMZ (100 μM) 
and at 24 and 96 hours post treatment FACS analysis was conducted (Figure 3C). We detected 
significant accumulation of asub-G1 cell population consistent with cell death post IP1867B 
treatment. At 96 hour post-treatment, TMZ exposure also increased the sub-G1 cell population, 
however this was significantly lower compared to IP1867B treated aHGG cells. 
We evaluated the aHGG transcription response post IP1867B exposure and examined a 
diverse range of cell death networks, the NF-κB pathway, and the inflammation response (Figure 3D, 
E and F). Three housekeeping genes Beta-2-microglobulin (B2M), hypoxanthine 
phosphoribosyltransferase 1 (HRPT1) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
were used for data normalization, and the fold change for each gene of interest was calculated. 12 
hours post IP1867B treatment, we noted a significant down regulation of various pro-inflammatory 
genes including interlukin (IL)12A, IL18, IL4, IL5, IL6, IL6-receptor, tumour necrosis factor (TNF), 
TNF-receptor 1A and TNF-receptor 11B (Figure 3G). When treated with IP1867B, aHGG cells 
directed a significant transcription increase in IL11. IL6 drives many of cancer hallmarks via the 
downstream activation of STAT3. IL11 has been shown to direct a more prominent role compared to 
IL6 in inflammation associated cancers, suggesting a potential compensatory mechanism directed by 
aHGG following IP1867B exposure [25]. These data raise the hypothesis that IP1867B could 
significantly complement a number of IL11 inhibitors (such as Bazedoxifene and mIL-11 Mutein) 
currently being tested in various gastrointestinal and breast cancers [25–27]. 
The related genes Insulin-like growth factor 1 (IGF1) and Insulin-like growth factor 1 
receptor (IGF1R) were identified by our analysis post-IP1867B treatment (Figure 3G). IGF1 and 
IGF1R both showed a highly significant expression decrease of 9.42 and 7.39 fold versus untreated 
aHGG cells respectively. IGF1 and IGF1R can confer chemo-resistance and have been considered 
important for EGFR inhibitor resistance [28]. These data suggested that IP1867B could significantly 
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inhibit IGF1 and IGF1R by potently reducing their expression and may, sensitise aHGGs to these 
therapeutics.  Following IP1867B treatment, we noted subtle, although statistically significant, 
increases in caspase 3, caspase 6 and caspase 9 expression supporting the induction of apoptosis 
(Figure 3G). We observed the direct repression of EGFR (2.73 fold reduction) post-IP1867B 
treatment of UP-029 aHGG cells. These aHGG lines showed significant EGFR over expression and 
suggested a second mechanism where IP1867B could significantly enhance the effectiveness of 
aHGG therapeutics, in particular EGFR inhibitors supported by IL4 and IL6 repression. 
We broadened our findings and included additional, recent biopsy-derived aHGG cell lines 
(Figure 4A, B and C). IP1867B directed an anti-inflammatory transcription response, characterized 
by the repression of IL6, IL6-receptor, TNF, TNF-receptor 1A and the significant induction of IL11. 
There was a significant reduction of EGFR, IGF1 and IGF1R transcription. We questioned if these 
transcriptional data were conserved at the protein level and noted that there was a considerable 
reduction of IGF1R, IL6R and EGFR protein expression post-IP1867B treatment in our aHGG cells 
(Figure 4D). These data raised the interesting hypothesis that IP1867B treatment could complement 
EGFR inhibitors.  We treated our aHGG cell lines with Gefitinib (EC50 5μM/L), AZD3759 (EC50 50 
nM) alone or in combination with IP1867B (Figure 4E and 4F). Adult HGG cells showed limited 
sensitivity to Gefitinib and AZD3759 however, when used in combination with IP1867B, there was 
a significant increase in sensitivity to each agent. Each inhibitor was effective as a significant loss of 
detectable pY1068-EGFR was noted following exposure with Gefitnib and AZD3759 (Figure 4G). 
EGFRvIII has been shown to be a direct regulator of STAT3. It was compelling that IP1867B 
treatment supressed this response [29]. IP1867B treatment in UP-029 and SEBTA-023 aHGG cells 
triggered a reduction in this network although we still detected, albeit reduced, EGFR and pY1068-
EGFR. In untreated, Gefitinib, or AZD3759, treated aHGG cells, there was robust detection of 
IGF1R. Post-IP1867B treatment there was a significant reduction of IGF1R protein expression. The 
IGF1R pathway is an important receptor tyrosine kinase (RTK) in aHGG tumours [23]. In aHGG 
cells with high IGF1R expression, we detected high levels of pSer473 AKT (Figure 4G). Neither 
Gefitinib nor AZD3759 had a significant impact on pSer473 AKT level, although IP1867B treatment 
noticeably reduced the level of pSer473 AKT. Concomitantly, we noted elevated FOXO3a-dependent 
gene expression post-IP1867B treatment (Figure 4H). These data indicated that there was significant 
suppression of the inflammation response and the IGF1R network, including AKT, which together 
increased the effectiveness of EGFR inhibitors.  
IP1867B effectively repressed aHGG growth in intracranial implanted tumours. 
The in vivo effectiveness of IP1867B was addressed using a U87-luciferase model. U87-MG-
luciferase aHGG cells were intracranially implanted into NOD/SCID mice (six mice per group) and 
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7 days post-inoculation, luciferase activity was measured. Tumour-bearing mice were treated on day 
1, 3, 5, 8, 10 and 12 by intraperitoneal (IP) injection of vehicle, IP1867B (30 mg/kg) or TMZ (50 
mg/kg) (Figure 5A). There was a significant reduction in luciferase expression in IP1867B treated 
mice and a significant increase in survival (Figure 5B). We collected the brain and liver of each 
animal. We noted significant intracranial tumour in vehicle treated mice, in particular, gross 
disruption of brain architecture and disruption of the midline. TMZ and IP1867B treated brains 
showed “normal” brain structure (Figure 5C). We carefully monitored animal weight and behaviour 
and noted there was no significant weight loss in IP1867B treatment group (Figure 5D). A concern 
regarding high dose aspirin treatment was potential damage and lesion development within the 
gastrointestinal tract. In an independent (non-tumour bearing mouse study) we examined if IP1867B 
oral administration induced any gastric mucosal lesions (Figure 5E). There were significantly less 
total mucosal membrane lesions in addition to significantly reduced lesion frequency (per mm) in 
IP1867B treated mice versus aspirin treated mice (Figure 5F).  
IP1867B treatment of tumour bearing mice significantly reduced IGF1 and IGF1R in vivo 
expression and, in agreement with our in vitro data, there was a significant down regulation of 
multiple inflammatory genes in the treated tumours (Figure 5G and 5H). There was an upregulation 
of caspase 3 and caspase 9 transcription in the IP1867B treated mice brains although this induction 
was not seen in the matched livers (data not shown). A number of apoptotic markers were upregulated 
in the brains and livers of TMZ treated mice. This was both tumour specific (as measured using 
human-specific primers) and systemic (determined using mouse specific primers). Following 
IP1867B exposure, there was a significant downregulation of EGFR protein expression in the tumours 
of treated mice (Figure 5I). This downregulation was not observed following mock or TMZ treatment 
regimens. 
4. Discussion 
The gold standard treatment for aHGG patients is the “Stupp protocol” with temozolomide. 
Despite this aggressive multi-modal regimen, patient prognosis remains poor with median survival 
of approximately 15 months. 
The nonsteroidal anti-inflammatory agent aspirin is widely used for preventing and treating 
cardiovascular and cerebrovascular diseases while recent cohort analysis has suggested that aspirin 
may prevent a range of cancers (including colon, gastric and pancreatic cancer) [30–33]. There is 
accumulating evidence that aspirin may act in different cell types, including epithelial cells, tumour 
cells, endothelial cells, platelet, and immune cells. Consequently, aspirin could act on multiple cancer 
hallmarks including cell growth, metastasis, angiogenesis and inflammation. There are noted side 
effects during long-term low dose aspirin treatment regimens that include nausea, vomiting, and 
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abdominal pain. An important clinical complication following long-term aspirin administration is 
gastrointestinal injury, in particular gastroduodenal destruction, ulceration, and haemorrhage(s) [34].  
The risk of major bleeding following aspirin treatment is higher in patients aged 75 years or older 
[34]. The median age at diagnosis of aHGG is 64 [35,36] where the incidence increases with age 
peaking between 75–84 years and this could present a major clinical obstacle for standard aspirin to 
be considered as a preventative or combinational therapy for aHGG patients. 
Here we evaluated, IP1867B, a “true liquid” aspirin formulation. IP1867B allowed a higher 
concentration of ASA to be delivered in vitro, directed a potent anti-aHGG response and was well 
tolerated by non-neoplastic astrocytes. Compared to each excipient component, IP1867B was 
synergistic and directed a potent anti-aHGG response independent of MGMT promoter methylation. 
There was induction of apoptosis following IP1867B treatment, consistent with caspase 3 cleavage. 
One of our biopsy-derived aHGG cells had no detectable p53 protein although was sensitive to 
IP1867B, suggesting that the mechanism of action was likely p53-independent. There was significant 
suppression of the NF-κB and IL6/STAT3 pathways and in particular suppression of EGFR 
transcription post-IP1867B exposure. We validated the suppression of EGFR transcription and noted 
the concomitant reduction of EGFR protein expression. A number of anti-EGFR clinical trials have 
been instigated and for aHGG [37,38]. Our data suggested that IP1867B could complement EGFR 
inhibitors. We evaluated Getfinib and AZD3759 alone and in combination with IP1867B. Dual 
treatment with IP1867B significantly increased the potency of two EGFR inhibitors and significantly 
reduced ser473-AKT phosphorylation in two in vitro aHGG models. We examined the transcription 
of IGF1 and IGF1R as these have been implicated in EGFR signalling and could inhibit AKT 
activation. IP1867B treatment significantly reduced IGF1 and IGF1R transcription. These data were 
highly unexpected and compelling as to date there are no blood-brain barrier permissive anti-IGF1 
and IGF1R treatments. Metabolic complications such as obesity, hyperglycemia, and type 2 diabetes 
are associated with poor outcomes in aHGG patients. To control peritumoral edema, high-dose 
steroids usage is common which can result in de novo diabetic symptoms. These could activate IGF1 
and IGF1R in aHGG cells. The administration of IP1867B could significantly attenuate these 
treatment complications noted in aHGG patients.  
IP1867B showed discernibly less propensity in producing gastric injury and induced 
significantly less gastric mucosal lesions compared to conventional aspirin.  There was no significant 
difference between vehicle and IP1867B treated mice. The IP administration of IP1867B caused a 
significant reduction in overall intracranial tumour mass and was well tolerated. Tumour-bearing 
mice showed no significant weight loss or behavioural changes indicative of tumour burden. Both in 
vitro and in vivo IP1867B treatment revealed a reduction of EGFR in addition to reduced IGF1 and 
IGF1R expression.  
   
Page | 10  
 
These data warrant follow-up in combination with EGFR inhibitors and validation of 
1P1867B as a putative IGF1 and IGF1R inhibitor. Care is required as IGF1 and IGF1R have important 
functions in metabolism thus the prolonged blockade of this pathway may be associated with adverse 
effects. Agents that can penetrate the blood-brain barrier and complement conventional and novel 
therapeutics are of significant interest and warrant follow-up investigation.  
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Fig. 1. IP1867B treatment of biopsy-derived aHGG cells significantly reduces cell viability. a-
d). Indicated aHGG cells (10,000 per well) were treated with varying dosages of each indicated 
compound and 96 h post treatment, MTS (Promega) assays were conducted. n = 3, error bars 
indicate ± StDev. e). Average Log2 EC50 concentration for each excipient shown. 2-tailed ANOVA 
analysis indicated by each bracket with P value and significance shown. n = 3 ± StDev. f). 
Representative microscopy images for each biopsy-derived aHGG cell line 24 h post IP1867B 
treatment (40× magnification). g). Average Log2 EC50 concentration 96 h post IP1867B treatment 
under normoxic or hypoxic conditions. 2-tailed ANOVA analysis indicated by each bracket 
with P value and significance shown. n = 3 ± StDev. 
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Fig. 2. IP1867B demonstrates synergy compared to each excipient component when patient-
derived aHGG cells are treated. a-d). Representative isobolograms from combination or single 
treatment of aspirin (SIGMA), triacetin, IP1867B or temozolomide in aHGG cell lines. a). UP-029, 
b). SEBTA-025, c). SEBTA-003, d). SEBTA-023 cells were treated with each effective 50% 
concentration. IP1867B (or temozolomide) was added to each cell line. EC50 values were determined 
from dose-response curves. The straight line connects the EC50 values for each agent alone and 
illustrates the theoretical values resulting in additive effects. Data points below the line represent 
synergistic (CI ≤ 0.8) and above the line antagonistic (CI ≥ 1.2) interactions. n = 3. e-f). 
Representative isobolograms from combination or single treatment of aHGG cells with IP167B and 
TMZ or aspirin and TMZ. n = 3 g). Representative isbologram dose curves for UP-029 aHGG cells 
treated with each indicated agent. h). CC2565 cells (10,000 per well) were treated with varying 
dosages of each indicated compound and 96 h post treatment, MTS (Promega) assays were 
conducted. n = 3, error bars indicate ± StDev. 
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Fig. 3. IP1867B directs significant cell death and suppression of key inflammatory networks in 
aHGGs. a). Representative immunoblots for caspase 3 cleavage following IP1867B or TMZ 
exposure. b). Total p53 accumulation and activation in aHGG cells post-IP1867B treatment. c). FACS 
analysis 96 h post-drug treatment. d-f). Volcano plots for cell death pathway, IL6/STAT3 and NF-κB 
signalling networks following IP1867B treatment of UP-029 aHGG cells. g). Key up and down-
regulated gene expression changes identified in d-f 24 h post-IP1867B treatment of UP-029 aHGG 
cells. n = 3, error bars indicate ± StDev with P values shown. 
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Fig. 4. IP1867B treatment significantly suppresses EGFR, IGF1 and IGF1R expression and 
enhances anti-EGFR therapeutics. a-c) Gene expression analysis in each indicated aHGG cell line 
24 h post IP1867B treatment n = 3, error bars indicate ± StDev. d). Representative immunoblots for 
each indicated protein 24 h post IP1867B treatment. e-f). UP-029 aHGG cells (10,000 per well) were 
treated with varying dosages of each indicated compound and EGFR-inhibitor and 96 h post 
treatment, MTS (Promega) assays were conducted. n = 3, error bars indicate ± StDev. g). 
Representative immunoblot for pSer473-AKT following treatment with each single or combination 
therapeutic. h). Expression of key FOXO3a-dependent genes 24 h post-treatment with each indicated 
therapeutic. n = 3, error bars indicate ± StDev. Two-tailed ANOVA analysis conducted for each 
bracket. * indicates P value ≤ 0.05. 
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Fig. 5. IP1867B IP treatment induces significant reduction of intracranial tumours. a) Overall 
luciferase signal at day 19 following IP treatment of U87-MG tumour bearing mice. Brackets indicate 
two-tailed ANOVA with P values shown for each. Significant reduction of U87-luciferase tumours 
19 days post IP1867B treatment. Representative tumour bearing mouse bioilluminescence images 
post treatment with vehicle only (NT), TMZ or IP1867B. b). Overall survival for each group 
following mock, TMZ or IP1867B IP administration. C). Representative whole brain images 
following PBS, IP1867B or TMZ treatment. White arrows highlight tumour/distortion following 
tumour growth d). Average mice weight following vehicle only, TMZ or IP1867B treatment on day 
7 or day 19 post tumour establishment. Brackets indicate two-tailed ANOVA analysis with P values 
shown for each comparison. e). Representative microscopic images of the gastric mucosa tract 
following control, aspirin or IP1867B oral delivery. f). (left) Quantitative analysis of gastrointestinal 
mucosal lesion formation following control, aspirin or IP1867B oral delivery. (right) lesion 
number/mm following the same treatment regimen shown in e-f. g-h). Gene expression analysis in 
U87-MG tumours treated with either IP1867B or TMZ at day 19 n = 3, error bars indicate ± StDev. 
i). Representative immunoblot for EGFR following in vivo treatment with each therapeutic at day 19. 
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